Replies to post #374571 on NorthWest Biotherapeutics Inc (NWBO)

[DavidW2]

If that is true, why NWBO stock dropped to 14 cents in year 2019?

49% living rate beyond 3 years is incredible.

[wavelengthy]

In her presentation (Nicks YouTube link), Linda Liau provides an updated 3yr survival stat @ 28.2% for the entire phase 3 ITT population.

The 49% figure you reference may be confused with the below data point from the recent blinded publication in the JTM: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6

For patients with methylated MGMT (n?=?131), mOS was 34.7 months from surgery, with a 3-year survival of 46.4%.

Encouraging stats nonetheless.

Wavelengthy

[CherryTree1]

Still blinded data on all 331 patients:
https://nwbio.com/updated-interim-data-from-phase-3-trial-of-dcvax-l-for-glioblastoma/
NOV 19 2018
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma

Survival at 3 years is 28.2%
Survival at 3 years for 41.1% (methylated)